Industry Standard Research
Toggle navigation
Register
Log In
Search for:
Reports
Full Report List
Manufacturing Reports
Service Provider Quality Benchmarking Reports
Trends & Technology Reports
Clinical Trial Recruitment & Retention Reports
Commercialization Reports
Department Models & Structures Reports
Biosimilars & Biologics Reports
Library Access Subscription
Targeted Distribution
Custom Research
Free Resources
Core Industry Metrics
Infographics
White Papers
Industry Statistics
About
ISR Health Panel
Our Customers
Community Involvement
Media Center
Careers
Contact Us
Home
>
Industry Statistics
Industry Statistics
Free Resource
Home
>
Industry Statistics
Hybrid vs. Traditional Clinical Trial Costs
Preferred Attributes When Selecting A Phase 2/3 CRO
Preferred Provider Type By Clinical Research Phase
Top Five Clinical Development Outsourcing Costs
Interest in Hybrid Trials Increases
Outsourcing Drivers For Small Molecule Manufacturing
Sources For Clinical Outcome Reporting And Assessments
Average Number Of EDC Systems Used—Current And Projected
Sponsor Interest In Current Phase I Trends
Phase 2/3 Outsourced Spend By Provider Type
Top 5 Challenges In Finding Rare Disease Patients
PPA Differences Between Small And Large Sponsors
Manufacturing Expenditure By Activity
Small & Emerging Outsourced Manufacturing Activities
Attributes Gaining Importance in Clinical Research
Use of Outside Consultants in Phase II/III Clinical Research
Technology in Clinical Trials: Differences by Company Size
Use of TMF Solutions in Clinical Development Studies
Pharmacovigilance Technology and the Adoption of AI
Sole Sourcing Arrangements for Central Labs
Stances on Implementing Virtual Trials
What Are The Most Common Site Start Up Strategies?
How Does Biopharma Outsource Clinical Logistics?
mHealth Implementation—Use By Therapeutic Area
What To Prioritize When Selecting A Phase 1 CRO
The Most Important Oral Dose Life Cycle Extension Strategies
The Geographic Distribution of 2019’s CRO Market Size
Trends In Phase IV Selection Drivers
How Prevalent Are PPAs In Phase II/III Research?
Are Outsourcers Interested In Changing Their CRO Mix?
What goes into a CRA Salary?
mHealth in Clinical Trials—Why and How?
Clinical Research M&A—A Slower Year
A Look at 2018’s CDMO Expansions
How Experience & Capacity Influence Biologic API Outsourcing
What Factors Influence Outsourcing Model Changes
The Interconnected World of Blockbuster Oncology Drugs
Changes In Manufacturing Pipeline Focus
Outsourcing Impact Of Focus On Innovative Treatment
The Top 5 Selection Drivers for Phase IV Services
Customer Loyalty in Small Molecule Drug Product Manufacturing
Marketed Biologics In 2023 By Type
Department Influence On CMO Selection
Approaches To CMC Involvement Across Drug Development
Customer Loyalty in Biologic Drug Product Manufacturing
Choosing a development stage eCOA/ePRO provider
Use of Preferred Providers among Small Molecule Outsourcers
What Will Drive Biologics Market Growth?
What are the largest slices of the CRO Market?
Use Of Preferred Providers Among Large Molecule Outsourcers
Small Molecule Outsourcing Drivers
Is the U.S. Biosimilar Industry Falling Behind?
Most Important Attributes For EDC Provider Selection: Development vs. Post-Marketing
Small Molecule API Contract Manufacturer Loyalty
Comparison Of Selling vs. Manufacturing Biosimilars
Trial Data Collection—Paper vs. Electronic
Benefits of Using Preferred Providers for Clinical Development Outsourcing
Outsourced Manufacturing: Large vs Small Molecule
10 Years of CRO Performance
The Evolution of IRT (or whatever you call it)
A Year’s Worth of Drug Approvals
What Drives CRO Preferred Provider Selection?
ISR CUSTOMERS
